Prostate Cancer - Results from #22980

Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract June 13, 2013

Functional and molecular imaging of localized and recurrent prostate cancer - Abstract June 13, 2013

PSA screening and deaths from prostate cancer after diagnosis-A population based analysis - Abstract June 13, 2013

Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening - Abstract June 13, 2013

Unmet needs in the prediction and detection of metastases in prostate cancer - Abstract June 13, 2013

Statement by NIH Director Francis Collins on U.S. Supreme Court ruling on gene patenting June 13, 2013

Breaking News: Can someone else patent your genes? No, according to a closely watched ruling from the U.S. Supreme Court Thursday morning June 13, 2013

ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: P June 13, 2013

ASCO 2013 - Poster: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial June 13, 2013

ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer June 13, 2013

ASCO 2013 - Poster: Randomized double-blind, comparative study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) vs ADT alone in newly diagnosed, high-risk, metastatic hormone-naïve prostate cancer June 13, 2013

ASCO 2013 - Poster: Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer June 13, 2013

ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA) June 12, 2013

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer - Abstract June 12, 2013

Pre-radiotherapy PSA level as a predictor for biochemical control in prostate cancer patients receiving radiotherapy after radical prostatectomy - Abstract June 12, 2013

Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: Multicenter cohort study - Abstract June 12, 2013

Radiotherapy in the management of prostate cancer after radical prostatectomy - Abstract June 12, 2013

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes - Abstract June 12, 2013

Prostate cancer detection by using digital rectal examination: Contemporary practice patterns in the United States - Abstract June 12, 2013

Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy - Abstract June 12, 2013

Page 1150 of 1437